期刊文献+

肺部疾患血浆氨基酸末端脑钠素前体水平的预测价值分析

N-terminal pro-B-type natriuretic peptide: a prognostic parameter in lung disease
原文传递
导出
摘要 目的通过观察肺部疾病及其合并左心功能不全患者血浆氨基酸末端脑钠素前体(N—terminal pro—B-type natriuretic peptide,NT—proBNP)水平的变化,及其对疾病预后的预测,探讨其变化规律及临床意义。方法利用酶联免疫吸附试验法测定81例肺部疾病患者血浆中NT—proBNP的浓度,其中未合并左心功能不全者68例,合并左心功能不全者13例;对照组(15例)为单纯心脏疾病引起左心功能不全者。同时进行动脉血气分析、静态肺功能以及超声心动图检查。结果在肺部疾病患者中,合并左心功能不全者血浆NT—proBNP水平明显高于未合并左心功能不全者(P=0.01);而与对照组相比差异无统计学意义。血浆NT—proBNP水平与右心室前后径、右心室流出道、估测肺动脉压力及左室舒张、收缩末期内径呈正相关;与射血分数呈显著负相关。NT—proBNP对于是否合并左心室功能不全的ROC曲线下面积为0.720;用于诊断肺部疾病合并肺动脉高压的ROC曲线下面积为0.719。采用多因素非条件Logistic回归发现,血浆NT—proBNP水平是影响肺部疾病患者住院期间病死率的主要因素。结论测定血浆NT—proBNP水平可以作为预测肺部疾病患者是否合并左心功能不全及预后的重要指标。 Objective To evaluate N-terminal pro-B-type natriuretic peptide(NT-proBNP) level as a parameter for the presence of left heart failure and mortality of hospital stay in patients with lung disease. Methods Plasma NT-proBNP level was measured in patients with lung disease (68 cases without left heart failure, 13 cases with left heart failure) and 15 patients with left heart failure because of eardiogenic reasons. Arterial blood gas analysis, echocardiography and pulmonary function testing were measured. Results Plasma level of NT-proBNP was significantly elevated in patients with left heart failure compared with that of patients without left heart failure (P = 0.01). NT-proBNP level correlated with pulmonary arterial pressure,internal diameter of outflow tract and anteroposterior diameter of right ventricle, internal diameter of end diastole and end-systole of left ventricle and ejection fraction. Roe analysis was done to assess the discriminatory ability of NT-proBNP for left heart failure and pulmonary hypertension in patients with lung disease. The area under the curve was respectively 0. 720 and 0. 719. NT-proBNP level served as a risk factor of death in duration of hospital stay by multivariate analysis. Conclusions NT-proBNP is a prognostic parameter in lung disease.
出处 《国际呼吸杂志》 2008年第24期1491-1495,共5页 International Journal of Respiration
关键词 肺部疾病 氨基酸末端脑钠素前体 预测价值 临床研究 Lung disease N-terminal pro-B-type natriuretic peptide
  • 相关文献

参考文献11

  • 1徐国宾,史晓敏.B型钠尿肽及N末端B型钠尿肽原在临床应用中值得关注的几个问题[J].中华检验医学杂志,2006,29(1):9-11. 被引量:71
  • 2叶任高.内科学.6版.北京:人民卫生出版社,2005:797.
  • 3荆志成.我国肺动脉高压专家共识阐释[J].中国实用内科杂志,2007,27(4):246-249. 被引量:53
  • 4Maisel A. B-type natriuretic peptide levels: a potential novel "white, count" for congestive heart failure. J Card Fail, 2001,7.. 183-193.
  • 5Bando M, Ishii Y, Sugiyama Y, et al. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonate. Respir Med, 1999,93 : 507-514.
  • 6Mariano-Goulart D, EberleMC, Boudousq V, et al. Major increase in brain natriuretic peptide indicates right ventricular systolic dysfunction in patients with heart failure. Eur J Heart Fail, 2003.5:181-488.
  • 7Yandle TG. Biochemistry of natriuretic peptides. J Intern Med, 1994,235:561-576.
  • 8Dao Q,Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-eare setting. J Am Coll Cardiol, 2001,37 : 379-385.
  • 9Souza R,Jardim C. Julio Cesar Fernandes C, et al. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respir Med, 2007,101 : 69-75.
  • 10Budweiser S, Luchner A, Jorres RA, et al. NT-proBNP in chronic hypercapnic respiratory failure: a marker of disease severity, treatment effect and prognosis. Respir Med, 2007,101 : 2003-2010.

二级参考文献18

  • 1荆志成,徐希奇.肺动脉高压现代分类和诊断策略[J].中华心血管病杂志,2004,32(12):1160-1162. 被引量:40
  • 2荆志成.六分钟步行距离试验的临床应用[J].中华心血管病杂志,2006,34(4):381-384. 被引量:98
  • 33rd World PAH Symposium. Pulmonary arterial hypertension: epidemiology, pathobiology, assessment and therapy [ J ]. J Am Coll Cardiol,2004,43 (12 Suppl S):1S-90S.
  • 4Rubin LJ. American College of Chest Physicians. Diagnosis and management of pulmonary arterial hypertension: ACCP evidencebased clinical practice guidelines [ J ]. Chest,2004,126 : 1 - 92.
  • 5Galie N,Torbicki A, Barst R, et al. ESC guidelines:guidelines on the diagnosis and treatment of pulmonary arterial hypertension [ J ].Eur Heart J,2004,25:2243 -2278.
  • 6Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension [ J ]. J Am Coll Cardiol,43 (12) :5 -12.
  • 7Mcgoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension [ J ]. Chest,2004,126:14 -34.
  • 8McQuillan BM, Picard MH, Leavitt M, et al. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects [ J ]. Circulation, 2001,104 :2797 - 2802.
  • 9Hoeper MM, Oudiz RJ, Peacock A, et al. End points and clinical trial designs in pulmonary arterial hypertension [ J ]. J Am Coll Cardiol,2004,43:48 - 55.
  • 10Sitbon O,Humbert M,Jas X,et al. Long-term response to calcium channel blockers in idiopathic pulmonary hypertension [ J ]. Circulation ,2005,111 : 3105 - 3111.

共引文献150

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部